{"id":"NCT05033561","sponsor":"Fidec Corporation","briefTitle":"Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants","officialTitle":"A Phase III Open-label Randomized Controlled Study to Evaluate the Safety and Immunogenicity of nOPV2 at Different Intervals of Administration in Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-12-16","primaryCompletion":"2022-05-24","completion":"2022-10-25","firstPosted":"2021-09-05","resultsPosted":"2024-08-23","lastUpdate":"2024-08-23"},"enrollment":905,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Poliomyelitis"],"interventions":[{"type":"BIOLOGICAL","name":"nOPV2","otherNames":[]}],"arms":[{"label":"2 doses, 1 week apart","type":"EXPERIMENTAL"},{"label":"2 doses, 2 week apart","type":"EXPERIMENTAL"},{"label":"2 doses, 4 week apart","type":"ACTIVE_COMPARATOR"}],"summary":"Study to determine immunogenicity and safety following administration of 2 doses of novel oral poliovirus vaccine type 2 (nOPV2) given at different intervals of 1 week or 2 weeks or the standard 4-week interval in infants","primaryOutcome":{"measure":"Seroconversion Rate at 1, 2 & 4 Weeks Interval","timeFrame":"Up to max 8 weeks","effectByArm":[{"arm":"Group A","deltaMin":253,"sd":null},{"arm":"Group B","deltaMin":269,"sd":null},{"arm":"Group C","deltaMin":277,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.05"},{"comp":"OG001 vs OG002","p":"0.05"}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["Dominican Republic"]},"refs":{"pmids":["38109921"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":298},"commonTop":["Fever","Abnormal crying","Vomiting","Diarrhoea","Loss of apetite"]}}